Connect with us

Business

Epizyme’s shares fall after receiving new FDA approval for cancer drug – MarketWatch

Published

on

post featured image
ADVERTISEMENT

Shares of Epizyme Inc.
EPZM,
-11.60%
were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or r…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Are You Getting Unsolicited Offers To Buy Your House? – NPR
Article feature image
Moving around China has changed since Covid — and the changes may be permanent – CNBC
Article feature image
Athira Pharma CEO placed on leave amid claims of altered images – STAT – STAT